Drugs / Dendritic cells
last change 30 days ago re-read 2 minutes ago

Dendritic cells

Cell therapy

Developed for
melanoma · glioblastoma · anaplastic astrocytoma · central nervous system neoplasm · diabetic kidney disease · endometrial cancer · ependymoma · female breast carcinoma
+12 more · glioma · head and neck cancer · HIV infectious disease · kidney cancer · malignant glioma · malignant pancreatic neoplasm · medulloblastoma · metastatic melanoma · non-small cell lung carcinoma · renal cell carcinoma · sarcoma · urinary bladder cancer
Investigated by
Clinica Universidad de Navarra, Universidad de Navarra · Radboud University Medical Center · Beijing Tiantan Hospital · Belarusian State Medical University · Cancer Research Institute, New York City · Dr. Nina Bhardwaj
+25 more · Dutch Cancer Society · Fudan University · Fukushima Medical University · Fundación Salud de los Andes · Hebei Yanda Hospital · Huashan Hospital · Hvidovre University Hospital · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus · Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS) · Masonic Cancer Center, University of Minnesota · National University of Colombia · PT. JES Kasih Nusantara Sejahterah · Prof. Dr. Silke Gillessen · Qingdao University · Rigshospitalet, Denmark · Rumah Sakit Pusat Angkatan Darat Gatot Soebroto · SOTIO a.s. · Shanghai Chest Hospital · Statens Serum Institut · Steinar Aamdal · Stichting Katholieke Universiteit · The First People's Hospital of Changzhou · Universitas Pertahanan Indonesia · Universitas Prima Indonesia · University of Yamanashi

Trials 19 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT01171469 Sep 2010 → May 2012 anaplastic astrocytoma, ependymoma, glioblastoma, medulloblastoma Masonic Cancer Center, University of Minnesota Completed No outcome recorded
Phase 1 NCT01149902 Jul 2010 → Mar 2012 head and neck cancer University of Yamanashi Unknown No outcome recorded
Phase 1 NCT00856154 Jan 2007 → Apr 2008 HIV infectious disease Statens Serum Institut Completed No outcome recorded
Phase 1 NCT00124124 Jul 2005 → Jul 2008 melanoma Dr. Nina Bhardwaj Completed No outcome recorded
Phase 1/28 trials
Phase 1/2 NCT06866158 May → Aug 2024 overdue diabetic kidney disease PT. JES Kasih Nusantara Sejahterah Active not recruiting No outcome recorded
Phase 1/2 NCT02496520 Sep 2014 → Sep 2018 central nervous system neoplasm, sarcoma Clinica Universidad de Navarra, Universidad de Navarra Completed No outcome recorded
Phase 1/2 NCT03450044 Jan 2014 → Jul 2018 female breast carcinoma Fundación Salud de los Andes Completed No outcome recorded
Phase 1/2 NCT01235845 Jan 2011 → Dec 2012 malignant glioma Qingdao University Unknown No outcome recorded
Phase 1/2 NCT00961844 Aug 2009 → Jun 2012 metastatic melanoma Steinar Aamdal Terminated No outcome recorded
Phase 1/2 NCT01944709 Aug 2006 → Dec 2007 melanoma Prof. Dr. Silke Gillessen Terminated No outcome recorded
Phase 1/2 NCT00847106 Mar 2004 → Oct 2005 melanoma Radboud University Medical Center Completed No outcome recorded
Phase 1/2 NCT00795977 Nov 2003 → Nov 2011 malignant pancreatic neoplasm Fukushima Medical University Unknown No outcome recorded
Phase 26 trials
Phase 2 NCT04184232 Jul 2019 → Dec 2020 urinary bladder cancer Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus Completed No outcome recorded
Phase 2 NCT04212377 Apr 2019 → Mar 2021 endometrial cancer Radboud University Medical Center Completed No outcome recorded
Phase 2 NCT02669719 Jan 2016 → Jan 2017 non-small cell lung carcinoma Shanghai Chest Hospital Unknown No outcome recorded
Phase 2 NCT02487550 Aug 2015 → Jul 2028 expected kidney cancer The First People's Hospital of Changzhou Not yet recruiting No outcome recorded
Phase 2 NCT01567202 Mar 2012 → Nov 2020 glioblastoma Huashan Hospital Unknown No outcome recorded
Phase 2 NCT00610389 Feb 2008 → Apr 2010 hepatocellular carcinoma, melanoma, renal cell carcinoma Clinica Universidad de Navarra, Universidad de Navarra Unknown No outcome recorded
Phase not applicable1 trial
NCT02771301 Feb 2016 → Jan 2019 glioma Hebei Yanda Hospital Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

FieldValueCited text
Known as Dendritic Cells “Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to...” NCT01567202
17

“Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.” NCT02487550

“In vitro generated dendritic cells are loaded with tumor derived peptides and injected subcutaneously.” NCT01944709

Dendritic cells (DCs) are immune cells that form part of the mammalian immune system.” NCT01235845

“DCL (Dendritic Cells+Lymphocytes) previously matured with S-Protein of SARS-CoV-2.” NCT06866158

NCT00124124

NCT01149902

NCT01171469

NCT02771301

NCT00961844

NCT02496520

NCT04184232

NCT03450044

NCT02669719

NCT04212377

NCT00847106

NCT00610389

NCT00795977

Known as DCs “Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to...” NCT01567202
Known as Peptides on autologous Dendritic Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT00856154
Modality Cell therapy “0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP.” NCT00124124
Route Other “0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP.” NCT00124124